Healthcare Industry News: Novartis Pharmaceuticals
News Release - October 4, 2006
Genentech Announces Vice President Appointments in Commercial Operations and Manufacturing
SOUTH SAN FRANCISCO, Calif., Oct. 4 (HSMN NewsFeed) -- Genentech, Inc. (NYSE: DNA ) today announced the appointment of Leonard Kanavy to vice president, Commercial Operations, and the promotion of Anthony P. Hurley to vice president, Fill/Finish Manufacturing.Leonard Kanavy
Vice President, Commercial Operations
Leonard Kanavy joins Genentech as vice president, Commercial Operations, reporting to Ian T. Clark, executive vice president, Commercial Operations. In this role, Kanavy will be responsible for leading the Market Planning, Forecasting, Sales Operations, Data Acquisition, Commercial Training, Commercial Business Processes, Thought Leader Management and Market Communications groups.
Kanavy joins Genentech from Novartis Pharmaceuticals, U.S., where he was vice president of Commercial Operations. Kanavy held several leadership roles at Novartis, including vice president of Business Analysis, executive director of Market Analysis, and director of Specialty Marketing Research & Analysis.
Kanavy holds a Bachelor of Science in management and a Master of Business Administration from the University of Scranton.
Anthony P. Hurley
Vice President, Fill/Finish Manufacturing
Anthony P. Hurley was promoted to vice president, Fill/Finish Manufacturing, reporting to Timothy L. Moore, vice president, South San Francisco Manufacturing. In this role, Hurley will continue to lead the South San Francisco (SSF) Commercial and Clinical Fill/Finish Operations, and will have overall responsibility for Genentech's future fill/finish facility in Hillsboro, Oregon, which is expected to be licensed and operational in 2010.
Hurley joined Genentech in 2005 as senior director, Parenteral Manufacturing Facility. Hurley has had increasing responsibilities, including leading the Packaging Operations, and most recently, the SSF Manufacturing and Utility Instrumentations Operations teams.
Prior to his employment with Genentech, Hurley was Site Director for GlaxoSmith Kline's Anti-Infectives Operation and held various manufacturing operations and strategic planning positions over his 17-year tenure with that company.
Hurley holds a Bachelor of Science in chemical technology from Cork Institute of Technology in Ireland, and a Master of Science in industrial engineering from Rutgers State University.
About Genentech
Founded 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, Calif., and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com .
Source: Genentech
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
